decemb
sever
patient
wuhan
hubei
china
diagnos
pneumonia
secondari
unknown
viru
respons
epidemiolog
alert
place
world
health
organ
date
decemb
januari
chines
scientist
isol
sever
acut
respiratori
syndrom
coronaviru
month
follow
caus
coronaviru
diseas
covid
spread
across
globe
result
current
pandem
time
review
diagnos
patient
associ
death
center
diseas
control
prevent
cdc
behalf
societi
infecti
diseas
pharmacist
herein
summar
current
evid
march
provid
guidanc
potenti
treatment
option
import
caution
reader
new
data
emerg
approxim
everi
hour
regard
clinic
characterist
treatment
option
outcom
optim
support
care
remain
mainstay
therapi
clinic
efficaci
subsequ
agent
still
investig
exist
preclin
clinic
data
antivir
therapi
deriv
virus
includ
first
report
middl
east
respiratori
syndrom
coronaviru
merscov
first
report
noncoronavirus
eg
ebola
viru
diseas
unclear
well
data
extrapol
furthermor
clinic
relev
antivir
vitro
activ
defin
halfmaxim
effect
concentr
ec
valu
remain
unclear
given
absenc
pharmacokineticpharmacodynam
clinic
data
equat
achiev
exposur
rel
valu
treatment
effect
final
vitro
data
compar
cautious
across
studi
given
potenti
variabl
test
methodolog
could
impact
perceiv
activ
antimicrobi
stewardship
program
includ
infecti
diseas
pharmacist
physician
forefront
emerg
prepared
encourag
reader
continu
assess
clinic
data
emerg
share
experi
within
commun
preferenti
evalu
agent
context
random
control
trial
gilead
scienc
inc
respons
ebola
outbreak
west
africa
activ
triphosph
nucleosid
form
remdesivir
bind
ribonucl
acid
rna
depend
rna
polymeras
act
rnachain
termin
display
potent
vitro
activ
ec
hour
vero
cell
similar
activ
demonstr
zoonot
coronavirus
ec
valu
demonstr
merscov
remdesivir
highli
select
viral
polymeras
therefor
expect
low
propens
caus
human
toxic
accordingli
sheahan
et
al
demonstr
wide
therapeut
index
remdesivir
human
airway
epitheli
cell
model
drug
also
display
high
genet
barrier
resist
coronavirus
long
intracellular
halflif
allow
oncedaili
dose
dose
investig
treatment
mg
intraven
iv
day
follow
mg
iv
daili
day
infus
minut
tabl
therapeut
efficaci
remdesivir
first
describ
anim
model
ebola
among
infect
rhesu
monkey
oncedaili
dose
result
suppress
viral
replic
protect
lethal
diseas
howev
human
studi
remdesivirtr
patient
ebola
experienc
mortal
rate
random
control
trial
experiment
therapi
conduct
respons
democrat
republ
congo
outbreak
result
earli
termin
studi
arm
worth
note
trial
activ
control
arm
mortal
rate
experiment
treatment
zmapp
merscov
sheahan
et
al
evalu
therapeut
efficaci
remdesivir
among
infect
mice
found
treatment
significantli
reduc
viru
lung
titer
weight
loss
lung
hemorrhag
lung
injuri
score
author
propos
import
earli
therapi
initi
diminish
viru
replic
promot
pulmonari
repair
remdesivir
demonstr
less
clinic
benefit
hightit
viru
inoculum
notabl
author
also
note
prophylact
remdesivir
diminish
merscov
replic
diseas
similar
find
murin
model
first
report
remdesivirtr
patient
unit
state
male
snohomish
counti
washington
receiv
treatment
hospit
day
ill
day
due
develop
pneumonia
persist
fever
patient
experienc
clinic
improv
neg
oropharyng
swab
hospit
day
although
nasopharyng
swab
remain
posit
advers
event
remdesivir
report
patient
consist
previou
case
report
use
virus
among
first
patient
confirm
cdc
unit
state
treat
remdesivir
via
compassion
use
protocol
patient
report
transient
gastrointestin
symptom
aminotransferas
elev
patient
reportedli
recov
author
unabl
assess
efficaci
safeti
remdesivir
base
lack
compar
confound
treatment
includ
concomit
use
corticosteroid
one
patient
clinic
trial
current
enrol
patient
unit
state
tabl
two
addit
trial
recruit
china
regist
clinicaltrialsgov
sever
diseas
mildmoder
diseas
remdesivir
may
also
obtain
compassion
use
emerg
investig
new
drug
eind
applic
process
time
review
request
compassion
use
must
submit
onlin
via
http
rdvcugilead
com
compassion
use
consid
hospit
patient
polymeras
chain
reaction
pcr
confirm
requir
mechan
ventil
enrol
clinic
trial
feasibl
patient
exclud
compassion
use
program
meet
criteria
evid
multiorgan
failur
receiv
vasopressor
hypotens
liver
diseas
defin
alanin
aminotransferas
alt
upper
limit
normal
uln
renal
impair
defin
creatinin
clearanc
crcl
mlmin
receiv
dialysi
continu
venoven
hemofiltr
inclus
exclus
criteria
compassion
use
may
chang
applic
encourag
review
date
criteria
potenti
patient
clinician
cogniz
typic
take
minimum
hour
institut
receiv
emerg
institut
review
board
author
requir
protocol
consent
form
gilead
us
food
drug
administr
fda
approv
eind
eventu
drug
shipment
clinician
coordin
local
inform
technolog
team
build
medic
order
sentenc
electron
health
record
time
patient
may
receiv
antivir
therapi
wait
period
must
immedi
discontinu
receiv
remdesivir
compassion
use
interest
note
adapt
clinic
trial
protocol
origin
state
remdesivir
prodrug
metabol
activ
form
substrat
impli
exist
drugdrug
interact
substrat
inhibitor
ritonavir
voriconazol
howev
protocol
also
state
although
remdesivir
substrat
vitro
coadministr
inhibitor
cyp
isoform
unlik
markedli
increas
remdesivir
level
metabol
like
predominantli
mediat
hydrolas
activ
unlik
former
latter
statement
substanti
well
describ
chemistri
molecul
nation
institut
allergi
infecti
diseas
contact
discrep
collabor
gilead
correct
reason
believ
signific
drug
interact
remdesivir
inhibitor
induc
like
emerg
clinic
evid
avail
vitro
data
suggest
remdesivir
promis
agent
treatment
institut
explor
clinic
trial
enrol
compassion
use
remdesivir
moderatetosever
patient
addit
clinic
data
eagerli
anticip
help
defin
role
agent
chloroquin
antimalari
agent
antiinflammatori
immunomodulatori
activ
gain
signific
interest
potenti
therapeut
option
manag
earli
februari
wang
et
al
demonstr
potent
vitro
activ
chloroquin
ec
hour
vero
cell
data
consist
previou
data
chloroquin
inhibitori
activ
merscov
variou
cell
line
ec
valu
demonstr
respect
find
support
clinic
use
chloroquin
dose
mg
mouth
twice
daili
numer
clinic
trial
china
outbreak
although
rational
dose
regimen
remain
unclear
peer
review
data
trial
current
unavail
announc
midfebruari
promis
earli
result
demonstr
per
gao
et
al
thu
far
result
patient
demonstr
chloroquin
phosphat
superior
control
treatment
inhibit
exacerb
pneumonia
improv
lung
imag
find
promot
virusneg
convers
shorten
diseas
cours
accord
news
brief
sever
advers
reaction
chloroquin
phosphat
note
aforement
patient
although
develop
encourag
suppli
issu
unit
state
cardiovascular
toxic
concern
limit
use
chloroquin
altern
hydroxychloroquin
compound
differ
chloroquin
singl
hydroxyl
group
garner
interest
hydroxychloroquin
perceiv
better
toler
chloroquin
led
longterm
usag
rheumatolog
disord
histor
limit
data
publish
assess
activ
hydroxychloroquin
coronavirus
biot
et
al
assess
compar
inhibitori
activ
chloroquin
hydroxychloroquin
vero
cell
author
demonstr
chloroquin
approxim
increas
potenc
ec
compar
hydroxychloroquin
ec
yao
et
al
perform
studi
assess
compar
vitro
activ
chloroquin
hydroxychloroquin
perform
pharmacologybas
pharmacokinet
pbpk
model
assess
compar
exposur
predict
activ
compound
lung
vitro
analys
vero
cell
demonstr
potenc
hydroxychloroquin
ec
greater
chloroquin
ec
inform
optim
dose
hydroxychloroquin
investig
perform
pbpk
model
analysi
investig
util
human
popul
pharmacokinet
rat
lung
penetr
data
compound
estim
free
trough
concentr
lung
ec
ratio
r
ltec
mg
chloroquin
mouth
twice
daili
report
demonstr
efficaci
target
r
ltec
hydroxychloroquin
regimen
set
day
day
day
r
ltec
valu
predict
efficaci
mg
mouth
twicedaili
dose
chloroquin
variou
dose
regimen
simul
particularli
notabl
first
oral
load
dose
mg
divid
mg
mg
day
follow
mg
daili
regimen
led
significantli
higher
r
ltec
day
day
day
valu
demonstr
chloroquin
second
regimen
load
dose
mg
mg
day
follow
mg
twice
daili
also
associ
higher
r
ltec
valu
chloroquin
day
correspond
respect
author
conclud
data
support
lower
dose
regimen
r
ltec
valu
significantli
higher
proven
efficaci
regimen
mg
chloroquin
mouth
twice
daili
clinician
note
chloroquin
hydroxychloroquin
halfliv
day
therefor
short
durat
would
like
provid
prolong
cours
therapi
exemplifi
pbpk
model
r
ltec
valu
hydroxychloroquin
predict
still
target
efficaci
threshold
day
even
cours
therapi
although
data
encourag
potenti
role
hydroxychloroquin
caution
sole
reli
data
support
dose
regimen
patient
use
mg
chloroquin
mouth
twice
daili
refer
efficaci
ration
given
initi
report
china
import
note
dose
still
requir
valid
improv
r
ltec
valu
report
larg
driven
find
hydroxychloroquin
time
potent
chloroquin
vitro
although
enhanc
potenc
may
well
prove
true
data
becom
avail
report
counter
rel
potenc
demonstr
structur
similar
strain
chloroquin
approxim
time
potent
hydroxychloroquin
addit
recent
publish
studi
demonstr
ec
valu
chloroquin
similar
valu
report
hydroxychloroquin
analysi
yao
et
al
current
efficaci
data
avail
hydroxychloroquin
addit
consider
given
optim
dose
strategi
use
follow
exampl
illustr
point
one
consid
compound
equal
potent
ident
ec
valu
util
pbpk
data
yao
et
al
mg
load
mg
daili
regimen
hydroxychloroquin
would
yield
r
ltec
valu
day
respect
r
ltec
valu
would
slightli
lower
achiev
mg
mouth
twice
daili
chloroquin
day
significantli
lower
day
suggest
potenti
need
higher
dose
similar
activ
although
mg
daili
regimen
common
regimen
current
assess
clinic
trial
rational
dose
current
unclear
least
clinic
trial
china
use
higher
dose
mg
mouth
daili
point
gautret
et
al
recent
publish
initi
experi
impact
mg
hydroxychloroquin
mouth
everi
hour
viral
erad
patient
author
report
patient
hydroxychloroquin
control
posit
abl
nasopharyng
sampl
first
day
therapi
treat
arm
investig
demonstr
hydroxychloroquin
superior
standard
care
p
erad
nasopharynx
interest
note
patient
prescrib
azithromycin
prevent
bacteri
superinfect
investig
found
viral
erad
numer
superior
subgroup
compar
receiv
hydroxychloroquin
alon
author
conclud
azithromycin
reinforc
viral
load
achiev
hydroxychloroquin
although
data
intrigu
certain
limit
data
set
must
acknowledg
first
although
viral
erad
import
endpoint
author
report
clinic
outcom
patient
second
cohort
initi
contain
hydroxychloroquin
patient
remov
analysi
due
earli
cessat
hydroxychloroquin
therapi
includ
pcrposit
patient
transfer
intens
care
unit
icu
pcrneg
patient
pass
away
pcrposit
patient
discontinu
hydroxychloroquin
due
nausea
final
hydroxychloroquin
monotherapi
arm
includ
patient
significantli
higher
viral
load
repres
lower
cycl
threshold
c
valu
receiv
combin
therapi
hydroxychloroquin
monotherapi
patient
c
valu
separ
c
valu
notabl
discord
viral
erad
rate
vs
latter
number
approach
demonstr
hydroxychloroquin
azithromycin
combin
therapi
patient
c
valu
given
find
small
number
studi
lack
clinic
outcom
present
potenti
addit
toxic
hydroxychloroquin
azithromycin
desper
need
practic
good
antimicrobi
stewardship
pandem
would
caution
clinician
use
data
support
combin
therapi
despit
unknown
initi
experi
china
encourag
potenti
role
chloroquin
altern
hydroxychloroquin
manag
clinician
encourag
close
follow
subsequ
peerreview
public
ongo
chloroquin
hydroxychloroquin
trial
other
rais
concern
regard
appar
vitro
andor
vivo
discord
wit
chloroquin
viral
infect
furthermor
hydroxychloroquin
util
care
consider
dose
select
given
accord
aforement
data
well
consider
initi
cours
ill
lopinavir
human
immunodefici
viru
hiv
proteas
inhibitor
administ
fixeddos
combin
ritonavir
lpvr
potent
inhibitor
boost
lopinavir
concentr
lopinavir
seem
block
main
proteas
inhibit
viral
replic
chu
et
al
evalu
seri
antivir
vitro
activ
report
lopinavir
ribavirin
inhibit
hour
incub
agent
synergist
use
togeth
de
wild
et
al
later
describ
antivir
activ
lopinavir
demonstr
ec
vero
cell
near
upper
rang
lpv
plasma
concentr
previous
measur
patient
hiv
sheahan
et
al
evalu
vitro
efficaci
lpvr
combin
interferon
beta
infb
merscov
found
addit
lpvr
significantli
enhanc
antivir
activ
infb
alon
ec
vs
iuml
respect
also
describ
ec
lpvr
lpv
alon
suggest
similar
activ
describ
sar
despit
vitro
activ
merscov
therapeut
dose
lpvr
infb
mice
model
fail
reduc
viru
titer
exacerb
lung
diseas
notabl
studi
remdesivir
demonstr
potent
vitro
activ
well
vivo
efficaci
howev
vivo
anim
data
merscov
appear
equivoc
given
nonhuman
primat
model
demonstr
improv
clinic
patholog
featur
lpvr
treatment
random
control
trial
lpvr
recombin
versu
placebo
current
enrol
patient
merscov
might
help
clarifi
appar
discrep
vitro
anim
model
base
vitro
find
chu
et
al
util
combin
therapi
lpvr
ribavirin
corticosteroid
newli
diagnos
patient
without
acut
respiratori
distress
syndrom
ard
start
april
patient
receiv
lpvr
combin
therapi
n
match
histor
patient
receiv
ribavirin
plu
corticosteroid
n
signific
reduct
develop
ard
death
day
observ
vs
p
corrobor
expand
casecontrol
match
studi
lpvrtreat
patient
center
demonstr
signific
reduct
puls
steroid
use
vs
intub
vs
mortal
vs
among
patient
receiv
lpvr
combin
versu
lpvr
respect
initi
therapi
import
benefit
lpvr
demonstr
patient
receiv
initi
treatment
lpvr
defin
initi
drug
time
diagnosi
observ
benefit
lpvr
ad
rescu
salvag
therapi
death
rate
vs
compel
mortal
differ
continu
investig
merscov
led
inclus
lpvr
chines
guidelin
dose
mg
capsulestablet
mouth
twice
day
day
even
though
knowledg
vitro
data
lpvr
exist
pediatr
patient
weigh
kg
recommend
dose
unit
state
mgkg
suspens
mouth
twice
daili
ongo
regist
clinic
trial
china
korea
thailand
hong
kong
evalu
lpvr
monotherapi
combin
antivir
eg
ribavirin
interferon
tradit
chines
medicin
treatment
realworld
data
treatment
lpvr
emerg
young
et
al
report
outcom
first
patient
infect
singapor
receiv
lpvr
monotherapi
three
patient
reduct
oxygen
requir
treatment
initi
deterior
respiratori
failur
two
patient
experienc
clearanc
viral
shed
treatment
experienc
advers
event
preclud
complet
plan
treatment
cours
publish
case
report
case
seri
korea
china
compris
total
patient
describ
decreas
viral
load
clinic
improv
lpvr
initi
data
difficult
interpret
light
concomit
drug
therapi
vari
time
point
therapi
initi
heterogen
sever
ill
amongst
patient
lack
compar
treatment
final
earli
report
wuhan
describ
patient
receiv
lpvr
addit
therapi
includ
corticosteroid
clinic
outcom
advers
event
either
describ
delin
treatment
group
recent
cao
et
al
report
result
openlabel
random
trial
compar
lpvr
mg
twice
daili
n
standard
care
n
treatment
pneumonia
primari
endpoint
defin
time
random
improv
point
ordin
scale
discharg
hospit
secondari
outcom
includ
mortal
time
discharg
virolog
respons
repeat
oropharyng
swab
cours
studi
median
time
symptom
onset
random
interquartil
rang
iqr
day
differ
group
signific
differ
time
clinic
improv
iqr
patient
receiv
lpvr
standard
care
patient
die
random
receiv
lpvr
remov
remain
differ
mortal
vs
absolut
differ
percentag
point
ci
import
differ
treatment
arm
reduct
viral
load
time
group
avail
data
difficult
assess
whether
lpvr
role
treatment
either
monotherapi
combin
data
encourag
must
weigh
inferior
perform
mous
model
merscov
less
potent
vitro
activ
compar
remdesivir
chloroquin
limit
data
suggest
advantag
standard
care
import
warrant
comment
recent
random
control
trial
pneumonia
median
time
symptom
onset
initi
therapi
day
experi
therapi
appear
effect
start
earli
rescu
andor
salvag
use
drug
interact
must
screen
gastrointestin
toxic
includ
diarrhea
nausea
vomit
hepatotox
requir
close
monitor
particularli
elev
aspart
transaminas
alt
may
exclud
patient
clinic
trial
lpvr
tablet
taken
without
regard
food
crush
decreas
system
exposur
solut
use
patient
receiv
intact
tablet
nitazoxanid
demonstr
potent
vitro
activ
sar
ec
hour
vero
cell
potent
activ
consist
ec
valu
nitazoxanid
activ
metabolit
tizoxanid
merscov
cell
ec
valu
respect
demonstr
nitazoxanid
display
broadspectrum
vitro
antivir
activ
influenza
respiratori
syncyti
viru
parainfluenza
rotaviru
noroviru
among
other
addit
coronavirus
broadspectrum
antivir
activ
believ
due
fact
mechan
action
base
interfer
hostregul
pathway
involv
viral
replic
rather
virusspecif
pathway
due
broadspectrum
antivir
activ
nitazoxanid
investig
manag
influenza
acut
respiratori
infect
posit
result
demonstr
phase
studi
outpati
manag
influenza
dose
mg
mouth
bid
nitazoxanid
associ
improv
time
resolut
symptom
compar
placebo
p
three
phase
random
control
trial
uncompl
influenza
sinc
complet
clinicaltri
gov
identifi
march
april
septemb
although
result
unavail
nitazoxanid
fail
reduc
durat
hospit
time
symptom
allevi
phase
random
control
trial
patient
sever
acut
respiratori
ill
requir
hospit
predominantli
caus
respiratori
virus
although
vitro
activ
nitazoxanid
encourag
data
clearli
need
determin
role
manag
tocilizumab
human
monoclon
antibodi
inhibit
membranebound
solubl
receptor
secret
monocyt
macrophag
one
main
driver
immunolog
respons
symptom
patient
cytokinereleas
syndrom
cr
although
tocilizumab
first
approv
fda
treatment
rheumatoid
arthriti
gain
traction
recent
year
treatment
patient
cr
follow
chimer
antigen
receptor
tcell
car
therapi
corticosteroidspar
agent
inde
receiv
fda
approv
sever
lifethreaten
car
tassoci
cr
due
efficaci
safeti
profil
although
criteria
grade
cr
sever
vari
cancer
center
propos
administ
tocilizumab
cr
patient
follow
oxygen
requir
hypotens
respons
fluid
low
dose
singl
vasoact
agent
grade
organ
toxic
defin
common
terminolog
criteria
advers
event
antagon
may
make
patient
suscept
bacteri
infect
associ
neutropenia
thrombocytopenia
patient
receiv
chronic
therapi
tocilizumab
giant
cell
arter
rheumatoid
arthriti
case
seri
adult
patient
relaps
refractori
bcell
acut
lymphoblast
leukemia
grade
cr
higher
associ
increas
risk
subsequ
infect
unclear
whether
tocilizumab
corticosteroid
use
promot
risk
report
advers
event
tocilizumabtr
patient
submit
fda
cr
indic
recommend
maximum
dose
treatment
hyperinflammatori
state
cytokin
storm
includ
elev
report
sever
associ
increas
mortal
patient
china
preprint
nonpeer
review
case
seri
patient
treat
tocilizumab
februari
china
report
mark
success
includ
rapid
resolut
fever
creactiv
protein
decreas
oxygen
requir
resolut
lung
opac
computer
tomographi
imag
author
state
patient
routin
treatment
week
tocilizumab
describ
standard
care
accord
nation
treatment
guidelin
includ
lopinavir
methylprednisolon
support
care
patient
analyz
tocilizumab
administr
mean
valu
pgml
normal
pgml
note
unit
state
monitor
sendout
laboratori
institut
turnaround
time
day
advers
event
describ
chines
cohort
howev
longterm
assess
done
immunotherapi
tocilizumab
list
treatment
option
sever
critic
case
elev
edit
nation
health
commiss
peopl
republ
china
diagnosi
treatment
guid
recommend
dose
mgkg
mg
standard
dose
iv
option
repeat
dose
hour
exceed
total
dose
mg
ongo
trial
china
evalu
safeti
efficaci
tocilizumab
patient
pneumonia
none
regist
unit
state
anticip
data
regard
tocilizumab
use
patient
emerg
imper
clinician
evalu
close
optim
time
tocilizumab
administr
diseas
cours
yet
defin
known
threshold
progress
sever
diseas
imper
continu
follow
longterm
outcom
patient
assess
risk
versu
benefit
tocilizumab
similar
sever
respiratori
tract
infect
signific
interest
controversi
surround
role
corticosteroid
manag
sever
pneumonia
due
coronavirus
potenti
benefit
agent
blunt
inflammatori
cascad
seen
sever
diseas
need
care
weigh
concern
secondari
infect
advers
event
complic
corticosteroid
therapi
data
assess
role
corticosteroid
adjunct
care
sever
coronaviru
merscov
pneumonia
difficult
interpret
given
retrospect
observ
natur
analys
signific
confound
indic
difficult
control
correct
addit
limit
sampl
size
patient
receiv
corticosteroid
higher
sever
ill
like
requir
invas
intervent
like
receiv
intens
care
addit
signific
heterogen
regard
time
corticosteroid
initi
significantli
impact
diseas
progress
likelihood
respons
featur
lead
patient
receiv
steroid
increas
risk
poor
outcom
addit
great
variat
agent
dosag
use
impact
safeti
efficaci
therefor
clinician
make
therapeut
decis
base
literatur
corticosteroid
need
keep
consider
mind
clinic
data
use
corticosteroid
infect
mix
multipl
analys
show
impact
outcom
one
report
demonstr
decreas
mortal
critic
ill
patient
other
document
wors
outcom
patient
receiv
steroid
includ
increas
time
viral
clearanc
increas
composit
endpoint
icu
admiss
death
merscov
receipt
corticosteroid
associ
delay
time
viral
clearanc
larg
cohort
n
infect
patient
howev
data
set
show
nonsignific
reduct
mortal
patient
receiv
corticosteroid
adjust
odd
ratio
ci
account
differ
group
regress
model
account
timevari
exposur
final
recent
evid
suggest
decreas
mortal
patient
ard
receipt
corticosteroid
vs
without
hazard
ratio
ci
demonstr
data
corticosteroid
inconsist
confus
inconclus
although
target
patient
corticosteroid
improv
outcom
may
exist
eg
cytokinerel
lung
injuri
may
develop
rapidli
progress
pneumonia
popul
remain
illdefin
clinician
need
care
weigh
risk
benefit
corticosteroid
individu
patient
level
need
riskbenefit
assess
individu
patient
care
consider
dose
exemplifi
diagnosi
treatment
guid
nation
health
commiss
peopl
republ
china
author
state
base
respiratori
distress
chest
imag
may
consid
glucocorticoid
equival
methylprednisolon
mgkgday
day
less
note
largedos
glucocorticoid
suppress
immun
system
could
delay
clearanc
recent
consensu
statement
chines
thorac
societi
recommend
lower
dose
mgkg
per
day
methylprednisolon
day
select
patient
care
consider
risk
benefit
random
control
trial
data
urgent
need
clearli
defin
role
corticosteroid
ribavirin
guanosin
analog
termin
rna
synthesi
first
approv
use
clinic
respiratori
syncyti
viru
viral
hemorrhag
fever
combin
interferon
hepat
c
mention
previous
see
lpvr
section
evalu
use
clinic
combin
corticosteroid
andor
interferon
absenc
treatment
option
howev
outcom
either
poor
illdefin
dose
requir
antivir
activ
sar
rang
gram
mouth
everi
hour
associ
excess
toxic
patient
wang
et
al
evalu
vitro
activ
ribavirin
found
ec
time
less
potent
remdesivir
risk
hematolog
toxic
high
dose
like
outweigh
potenti
clinic
benefit
therefor
ribavirin
consid
viabl
candid
investig
research
develop
plan
given
lack
vitro
efficaci
toxic
profil
poor
outcom
interferon
may
stimul
innat
antivir
respons
expect
vitro
activ
given
previous
describ
activ
demonstr
merscov
ec
iuml
howev
toxic
substanti
includ
sever
cytopenia
hepatotox
includ
fatal
neuropsychiatr
event
risk
develop
fatal
lifethreaten
ischemia
infect
particularli
combin
ribavirin
combin
associ
improv
mortal
enhanc
viral
clearanc
retrospect
analysi
patient
infect
merscov
initi
combin
therapi
within
day
icu
admiss
despit
limit
poor
data
chines
guidelin
recommend
ribavirin
mg
iv
time
daili
combin
lpvr
inhal
million
unit
nebul
twice
daili
one
standard
treatment
option
variou
combin
ribavirin
interferon
antivir
agent
current
studi
sever
clinic
trial
base
poor
vitro
activ
absenc
anim
human
data
support
use
signific
toxic
profil
recommend
avoid
use
ribavirin
patient
time
although
interferon
may
use
adjunct
care
pose
signific
risk
critic
ill
patient
absenc
support
data
also
current
recommend
given
antivir
activ
influenza
consider
attent
paid
oseltamivir
lesser
degre
baloxavir
potenti
treatment
option
exacerb
initi
report
huang
et
al
wuhan
patient
manag
receiv
oseltamivir
addit
broadspectrum
antimicrobi
import
note
use
oseltamivir
target
therapi
rather
driven
lack
knowledg
caus
pathogen
time
treatment
desir
empir
treat
influenza
author
suggest
use
oseltamivir
public
data
suggest
vitro
activ
oseltamivir
fact
data
assess
oseltamivir
activ
coronavirus
demonstr
ineffect
inhibit
even
concentr
coronavirus
util
neuraminidas
thu
enzym
inhibit
oseltamivir
would
hold
true
zanamivir
peramivir
neuraminidas
inhibitor
agent
similarli
neither
defin
mechan
vitro
data
suggest
baloxavir
would
demonstr
activ
coronavirus
therefor
given
critic
need
agent
manag
influenza
concern
drug
shortag
oseltamivir
agent
avoid
patient
influenza
rule
tabl
list
agent
investig
andor
theoret
consid
manag
patient
time
recommend
made
agent
gener
avoid
without
addit
support
evid
appropri
manag
strategi
patient
rapidli
evolv
therapeut
challeng
optim
agent
treat
infect
prevent
progress
critic
ill
remain
illdefin
although
certain
agent
list
review
encourag
potenti
benefit
therapi
like
outweigh
rel
minor
risk
advers
event
shortcours
therapi
evid
remain
inconclus
chang
almost
daili
patient
popul
warrant
therapi
time
initi
therapi
need
defin
given
diseas
progress
occur
rapidli
stabl
patient
viral
load
highest
earli
infect
cours
author
review
opin
rapid
initi
therapi
highrisk
popul
patient
hospit
outpati
high
risk
complic
ration
consid
ideal
context
wellcontrol
adequ
power
trial
import
howev
strategi
without
risk
need
weigh
potenti
advers
event
remain
poorli
defin
impend
drug
shortag
increas
use
agent
help
address
concern
care
consider
given
durat
therapi
mani
clinic
trial
institut
protocol
recommend
day
uncompl
diseas
durat
therapi
individu
patient
progress
diseas
clinician
must
continu
monitor
adapt
new
literatur
becom
avail
caution
appli
bulk
avail
clinic
data
uncontrol
peer
review
even
unpublish
given
safeti
efficaci
convalesc
plasma
transfus
patient
establish
protocol
exist
current
unit
state
protocol
reportedli
develop
john
hopkin
univers
hospit
darunavircobicistat
proteas
inhibitor
current
evalu
clinic
trial
vitro
human
data
exist
support
use
time
thiuram
deriv
block
alcohol
oxid
demonstr
abil
competit
inhibit
papainlik
proteas
sar
howev
clinic
data
exist
vitro
clinic
data
exist
human
monoclon
igg
antibodi
bind
complement
protein
prevent
format
membran
attack
complex
mac
evalu
clinic
trial
quell
immun
respons
data
exist
time
support
use
favipiravir
rnadepend
rna
polymeras
inhibitor
broadspectrum
antivir
activ
howev
demonstr
high
ec
decreas
potenc
effect
protect
mice
ebola
viru
despit
similarli
high
ec
valu
current
evalu
clinic
trial
patient
agent
fda
approv
avail
unit
state
galidesivir
nucleosid
rna
polymeras
inhibitor
report
wide
spectrum
antivir
activ
current
pipelin
biocryst
pharma
previous
evalu
ebola
hemorrhag
fever
viru
infect
algaederiv
lectin
potent
hiv
entri
inhibitor
agent
demonstr
vitro
activ
ivig
ivig
remain
critic
nation
shortag
unit
state
benefit
patient
unclear
nelfinavir
proteas
inhibitor
might
activ
base
preprint
public
util
homolog
model
clinic
data
exist
anthelminth
drug
vitro
efficaci
howev
low
absorpt
oral
bioavail
result
wide
rang
serum
concentr
healthi
volunt
singl
dose
may
limit
util
antivir
treatment
human
monoclon
antibodi
discov
regeneron
reportedli
bind
protein
merscov
current
phase
trial
healthi
volunt
compani
reportedli
announc
recruit
phase
trial
howev
regist
clinicaltrialsgov
sarilumab
receptor
antagonist
fdaapprov
rheumatoid
arthriti
recent
announc
usbas
trial
begin
enrol
medic
center
new
york
patient
sever
diseas
sofosbuvir
antivir
use
treat
hepat
c
vitro
activ
clinic
data
exist
novel
fulli
human
tiziana
life
scienc
compani
recent
announc
move
forward
clinic
develop
patient
use
patient
excess
product
vitamin
c
ongo
clinic
trial
gram
iv
bid
vitamin
c
china
treatment
use
agent
recommend
time
chines
herbal
medicin
extract
infus
formul
given
ml
iv
twice
daili
suggest
may
consid
treatment
sever
critic
case
nation
health
commiss
peopl
republ
china
diagnosi
treatment
guid
edit
previous
demonstr
improv
mortal
patient
sever
commun
acquir
pneumonia
china
limit
critic
institut
clinician
report
experi
manag
treatment
medic
commun
may
modifi
optim
treatment
recommend
pathway
